Leukemia, MyeloidPhase 3IDHENTIFYNCT02577406
An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation
A Phase 3 study testing AG-221, BSC and Azacitidine in people with Leukemia, Myeloid and Isocitrate Dehydrogenase, run by Celgene at 93 sites in 18 countries.
Trial summary
This is an international, multicenter, open-label, randomized, Phase 3 study comparing the efficacy and safety of AG-221 versus conventional care regimens (CCRs) in subjects 60 years or older with acute myeloid leukemia (AML) refractory to or relapsed after second- or third-line AML therapy and positive for an… Read more about this study
- Who is it for?
- Ages 60 years and older
- Conditions the study is for
- Leukemia, Myeloid, Isocitrate Dehydrogenase
- What is being tested?
- AG-221, BSC and Azacitidine
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 319 participants
- Where
- 93 sitesin 18 countries
- Study dates
- 30 Dec 2015to 25 Mar 2024
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 60 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Subjects must satisfy the following criteria to be enrolled in the study:
- Subject is ≥ 60 years of age at the time of signing the ICF
- Subject has primary (ie, de novo) or secondary (progression of MDS or myeloproliferative neoplasms ([MPN], or therapy-related) AML according to WHO classification (Appendix B)
- Subject has received second- or third-line of AML therapy (see Appendix G for the definition of prior AML line; note that, for subjects having AML secondary to prior higher risk [Intermediate-2 or High risk according to the International Prognostic Scoring System] MDS treated with a hypomethylating agent [eg, azacitidine or decitabine], the hypomethylating therapy can be counted as a line if there is disease progression to AML during or shortly [eg, within 60 days] after the hypomethylating therapy.)
- Subject has the following disease status:
- Refractory to or relapsed after second- or third-line of intensive therapy for AML (eg, the "7 + 3" regimen):
Show all 24Show fewer
- at least 5% leukemic blasts in bone marrow (the minimum number of treatment cycles of the intensive therapy is per the investigator's discretion); or
- Refractory to or relapsed after second- or third-line low-intensity AML therapy (eg, LDAC, azacitidine or decitabine):
- at least 5% leukemic blasts in bone marrow after at least 2 treatment cycles
- Subject is eligible for and willing to receive the pre-selected CCR treatment option, according to the investigator's assessment (Note: Subjects with degenerative and toxic encephalopathies, especially after the use of methotrexate or treatment with ionizing radiation, should not receive cytarabine.)
- Subject has Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 (Appendix D)
- Subject has IDH2 gene mutations tested centrally (using the "investigational use only"PCR assay, Abbott RealTime IDH2) in samples of bone marrow aspirate and peripheral blood, and confirmed positive in bone marrow aspirate and/or peripheral blood. (Note: in the event that the central laboratory result is delayed and precludes acute clinical management of a subject who has confirmed IDH2 gene mutation by local evaluation, the subject may be eligible for randomization with approval by the Medical Monitor.)
- Subject has adequate organ function defined as:
- Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase (SGPT) ≤ 3 x upper limit of normal (ULN), unless considered due to leukemic organ involvement, following review by the Medical Monitor; and
- Serum total bilirubin ≤ 1.5 x ULN, unless considered due to Gilbert's syndrome (eg, a gene mutation in UGT1A1) or leukemic organ involvement, following review by the Medical Monitor; and
- Creatinine clearance > 30 mL/min based on the Modification of Diet in Renal Disease (MDRD) glomerular filtration rate (GFR):
- GFR (mL/min/1.73 m2) = 175 × (serum creatinine)-1.154 × (Age)-0.203 × (0.742 if female) × (1.212 if African American)
- Females of childbearing potential (FCBP)* may participate, providing they meet the following conditions:
- Agree to practice true abstinence from sexual intercourse or to use highly effective contraceptive methods (eg, combined [containing estrogen and progestogen] or progestogen-only associated with inhibition of ovulation, oral, injectable, intravaginal, patch, or implantable hormonal contraceptive; bilateral tubal occlusion; intra-uterine device; intrauterine hormone-releasing system; or male partner sterilization [note that vasectomized partner is a highly effective birth control method provided that partner is the sole sexual partner of the FCBP trial participant and that the vasectomized partner has received medical assessment of the surgical success]) at screening and throughout the study, and for 4 months following the last study treatment (6 months following the last dose of cytarabine); and
- Have a negative serum β-subunit of human chorionic gonadotropin (β-hCG) pregnancy test (sensitivity of at least 25 mIU/mL) at screening; and
- Have a negative serum or urine (investigator's discretion under local regulations) β-hCG pregnancy test (sensitivity of at least 25 mIU/mL) within 72 hours prior to the start of study treatment in the Treatment Phase (note that the screening serum pregnancy test can be used as the test prior to the start of study treatment in the Treatment Phase if it is performed within the 72-hour timeframe).
- Male subjects must agree to practice true abstinence from sexual intercourse or to the use of highly effective contraceptive methods (as described above) with non-pregnant female partners of childbearing potential at screening and throughout the course of the study, and should avoid conception with their partners during the course of the study and for 4 months following the last study treatment (6 months following the last dose of cytarabine; 6 months following the last dose of azacitidine in Canada)
- Subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted
- Subject is willing and able to adhere to the study visit schedule and other protocol requirements
Who cannot join
- The presence of any of the following will exclude a subject from enrollment:
- Subject is suspected or proven to have acute promyelocytic leukemia based on morphology, immunophenotype, molecular assay, or karyotype
- Subject has AML secondary to chronic myelogenous leukemia
- Subject has received a targeted agent against an IDH2 mutation
- Subject has received systemic anticancer therapy or radiotherapy < 14 days prior to the start of study treatment. Note that hydroxyurea is allowed prior to the start of study treatment for the control of leukocytosis (however, hydroxyurea should not be given within 72 hours prior to and after administration of azacitidine).
- Subject has received non-cytotoxic or investigational agents < 14 days or 5 half-lives, whichever is longer, prior to the start of study treatment
Show all 30Show fewer
- Subject has undergone HSCT within 60 days prior to the start of study treatment, or on immunosuppressive therapy post HSCT at the time of screening, or with clinically significant graft-versus-host disease (GVHD). The use of a stable dose of oral steroid post-HSCT and/or topical steroids for ongoing skin GVHD is permitted.
- Subject has persistent, clinically significant non-hematologic toxicities from prior therapies
- Subject has or is suspected of having central nervous system (CNS) leukemia. Evaluation of cerebrospinal fluid is only required if CNS involvement by leukemia is suspected during screening.
- Subject has active uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment)
- Subject has immediately life-threatening, severe complications of leukemia such as uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated intravascular coagulation
- Subject has significant active cardiac disease within 6 months prior to the start of study treatment, including New York Heart Association (NYHA) class III or IV congestive heart failure (Appendix E); acute coronary syndrome (ACS); and/or stroke; or left ventricular ejection fraction (LVEF) < 40% by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan obtained within 28 days prior to the start of study treatment
- Subject has prior history of malignancy, other than MDS, MPN or AML, unless the subject has been free of the disease for ≥ 1 year prior to the start of study treatment.
- However, subjects with the following history/concurrent conditions are allowed:
- Basal or squamous cell carcinoma of the skin
- Carcinoma in situ of the cervix
- Carcinoma in situ of the breast
- Incidental histologic finding of prostate cancer (T1a or T1b using the tumor, node, metastasis clinical staging system)
- Subject is known seropositive or active infection with human immunodeficiency virus (HIV), or active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)
- Subject is known to have dysphagia, short-gut syndrome, gastroparesis, or other conditions that limit the ingestion or gastrointestinal absorption of drugs administered orally
- Subjects has uncontrolled hypertension (systolic blood pressure [BP] > 180 mmHg or diastolic BP > 100 mmHg)
- Subject is a pregnant or lactating female
- Subject has known or suspected to have hypersensitivity to any of the components of study treatment
- Subject is taking those medications (listed in Section 8.2) that are known to prolong QT interval unless the subject can be transferred to other medications at least 5 half-lives prior to the start of study treatment
- Subject has QTc interval (ie, Fridericia's correction [QTcF]) ≥ 450 ms or other factors that increase the risk of QT prolongation or arrhythmic events (eg, heart failure, hypokalemia, family history of long QT interval syndrome) at screening
- Subject is taking the following sensitive CYP substrate medications that have a narrow therapeutic range are excluded from the study unless the subject can be transferred to other medications at least 5 half-lives prior to the start of study treatment: paclitaxel and docetaxel (CYP2C8), phenytoin (CYP2C9), S-mephenytoin (CYP2C19), thioridazine (CYP2D6), theophylline, and tizanidine (CYP1A2)
- Subject is taking the breast cancer resistance protein (BCRP) transporter-sensitive substrate rosuvastatin should be excluded from the study unless the subject can be transferred to other medications at least 5 half-lives prior to the start of study treatment
- Subject has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study
- Subject has any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study
- Subject has any condition that confounds the ability to interpret data from the study
Trial locations and contacts
93 sites in 18 countries.
93 sites in 18 countries
United States12 sites
Roswell Park Cancer Institute
Buffalo, New York, 14263
Local Institution - 111
Chicago, Illinois, 60637
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106
Baylor Sammons Cancer Center
Dallas, Texas, 75246
Duke University Medical Center
Durham, North Carolina, 27705
Local Institution - 104
Greenville, South Carolina, 29615
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey, 07601
Local Institution - 121
Miami, Florida, 33136
Local Institution - 128
New York, New York, 10029
University of Florida Health Cancer Center at Orlando Health
Orlando, Florida, 32806
Strong Health System
Rochester, New York, 14642
Montefiore Medical Center Albert Einstein Cancer Center
The Bronx, New York, 10467
China10 sites
Local Institution - 885
Beijing, 100080
Local Institution - 884
Beijing, 100191
Local Institution - 892
Beijing, 100853
Local Institution - 888
Chengdu, Sichuan, 610041
Local Institution - 882
Fuzhou, 350001
Local Institution - 881
Guangzhou, Guangdong, 510080
Local Institution - 883
Hangzhou, 310006
Local Institution - 887
Shanghai, 200025
Local Institution - 891
Shanghai, 200433
Local Institution - 889
Zhengzhou, 0
France10 sites
Local Institution - 606
Angers, 49033
Local Institution - 605
Bobigny, 93009
Local Institution - 602
Lille, 59037
Local Institution - 612
Marseille, 13273
Local Institution - 601
Nantes, 44093
Local Institution - 607
Pessac, 33604
Local Institution - 611
Pierre-Bénite, 69495
Local Institution - 609
Toulouse, 31009
Local Institution - 610
Versailles, 78000
Local Institution - 604
Villejuif, 94805
Germany8 sites
Local Institution - 403
Dresden, D-01307
Local Institution - 413
Essen, 45122
Local Institution - 406
Frankfurt, 60590
Local Institution - 401
Hanover, 30625
Local Institution - 412
Leipzig, 04103
Local Institution - 402
Mainz, 55131
Local Institution - 409
München, 81377
Local Institution - 407
Ulm, 89081
Italy7 sites
Local Institution - 305
Bologna, 40138
Local Institution - 304
Brescia, 25123
Local Institution - 302
Florence, 50139
Local Institution - 301
Naples, 80131
Local Institution - 306
Palermo, 90146
Local Institution - 303
Reggio Calabria, 89100
Local Institution - 307
Roma, 00133
Spain6 sites
Local Institution - 706
Avda, Campanar 21, 46009
Local Institution - 708
Barcelona, 08035
Local Institution - 704
Barcelona, 8036
Local Institution - 701
Oviedo, Principality of Asturias, 33011
Local Institution - 709
Salamanca, 37007
Local Institution - 702
Seville, 41013
United Kingdom6 sites
Local Institution - 501
London, EC1A 7BE
Local Institution - 507
London, SE5 9RS
Local Institution - 502
Manchester Withington, M20 4BX
Local Institution - 503
Nottingham, Nottinghamshire, NG5 1PB
Local Institution - 510
Oxford, OX3 9DU
Local Institution - 509
Sutton (Surrey), SM2 5PT
Brazil5 sites
Local Institution - 251
Jaú, 17210-080
Local Institution - 250
Porto Alegre, Rio Grande do Sul, 90020-090
Local Institution - 252
Porto Alegre, RS, Rio Grande do Sul, 90035-003
Local Institution - 253
Rio de Janeiro, 20211-030
Local Institution - 254
São Paulo, 01308-050
Turkey (Türkiye)5 sites
Local Institution - 873
Ankara, 06100
Local Institution - 872
Ankara, 06200
Local Institution - 871
Ankara, 6500
Local Institution - 874
Denizli, 20070
Local Institution - 875
Gaziantep, 27310
Australia4 sites
Local Institution - 904
Adelaide, South Australia, 5000
Local Institution - 901
Concord, New South Wales, 2139
Local Institution - 906
East Melbourne, 3002
Local Institution - 905
Melbourne, 3004
Canada4 sites
Local Institution - 202
Edmonton, Alberta, T6G2V2
Local Institution - 204
Montreal, Quebec, H3A 1A1
Local Institution - 201
Toronto, Ontario, M5G 2M9
Local Institution - 203
Winnipeg, Manitoba, R3E OV9
Denmark4 sites
Local Institution - 834
Aalborg, DK-9000
Local Institution - 833
Arhus C, DK-8000
Local Institution - 831
Copenhagen, 2100
Local Institution - 832
Odense, DK-5000
Russia4 sites
Local Institution - 861
Krasnoyarsk, 660022
Local Institution - 864
Moscow, 123182
Local Institution - 863
Moscow, 129301
Local Institution - 862
Saint Petersburg, 191024
Taiwan3 sites
Local Institution - 942
Taichung, Northern Dist., 404
Local Institution - 940
Taipei, Zhongzheng Dist., 10002
Local Institution - 941
Taoyuan, 333
South Korea2 sites
Local Institution - 953
Hwasun-gun, 519-809
Local Institution - 952
Seoul, 137-701
About this study
Official title: A Phase 3, Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation
This is an international, multicenter, open-label, randomized, Phase 3 study comparing the efficacy and safety of AG-221 versus conventional care regimens (CCRs) in subjects 60 years or older with acute myeloid leukemia (AML) refractory to or relapsed after second- or third-line AML therapy and positive for an isocitrate dehydrogenase (IDH2) mutation.
Read the detailed description
Acute myeloid leukaemia (AML) is a form of cancer that is common in older patients. Mutations in the isocitrate dehydrogenase enzyme 2 (IDH2) have been found in approximately 15% of patients with AML.
The outcome of first line chemotherapy treatment is poor and many patients fail to attain complete remission (CR, ie refractory) or will eventually relapse. There is no single standard of care for relapsed or refractory AML. Since the prognosis is very poor there is a great need for new therapies.
Inhibition of the mutant IDH2 enzyme may represent a promising targeted therapy for AML. AG-221 is a small molecule inhibitor of the IDH2 enzyme, designed to preferentially target the mutant IDH2 variants. Data from the ongoing first-in-human study has shown AG-221 to be generally well tolerated and demonstrated CR in patients with IDH2 mutation positive relapsed or refractory AML.
The study purpose is to test the safety and efficacy of AG-221 compared with conventional care regimens (CCR), which include best supportive care (BSC) only, azacitidine plus BSC, low-dose cytarabine plus BSC or intermediate-dose cytarabine plus BSC, in patients with late stage AML refractory to or relapsed after second or third line therapy and positive for the IDH2 mutation. Patients will be randomly assigned to receive open-label tablets of AG-221 or one of the CCR on continuous 28-day treatment cycles. The trial duration is expected to be 78 months which includes 42 months enrollment, approximately 7 months treatment and a follow-up period.
Study procedures include: vital signs, physical exams, ECGs, ECHO, urine/blood samples, bone marrow aspirates and/or biopsies and peripheral blood to test for IDH2 and assess treatment response. Bone marrow, blood, cheek swab samples will be used for genetic tests.
This study is being sponsored by Celgene Corporation. Approximately 316 participants will take part in the study.
- Conditions
- Leukemia, Myeloid, Isocitrate Dehydrogenase
- Being tested
- AG-221, BSC, Azacitidine, Low-dose cytarabine (LDAC), Intermediate-dose cytarabine (IDAC)
- Keywords
- AG-221, CC-90007, Efficacy, Safety, Leukemia, Acute myeloid meukemia, Isocitrate dehydrogenase 2 mutation, Enasidenib
- Medical subject headings
- Leukemia, Myeloid, Leukemia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AG-221Drug
Continuous 28-day cycles of AG 221 100 mg orally (PO) once a day (QD) for 28 days
BSCOther
Best supportive care includes, hydroxyurea for leukocytosis and/or differentiation-like syndrome, anti-infectives, analgesics, antiemetics, antipyretics, transfusions and nutritional support
AzacitidineDrug
continuous 28-day cycles of azacitidine 75 mg/m2/day SC for 7 days, plus BSC
Low-dose cytarabine (LDAC)Drug
continuous 28-day cycles of cytarabine 20 mg SC twice a day (BID) for 10 days, plus BSC
Intermediate-dose cytarabine (IDAC)Drug
28-day cycles of cytarabine 0.5 to 1.5 g/m2/day IV for 3 to 6 days, per standard institutional practice, plus BSC; only BSC given after IDAC therapy concludes per standard institutional practice
| Study group | Role | What they receive |
|---|---|---|
| AG-221 plus Best supportive care (BSC) | Experimental | Continuous 28-day cycles of AG 221 100 mg orally (PO) once a day (QD) for 28 days, plus BSC. Receives: Drug: AG-221; Other: BSC |
| Conventional care regimen (CCR) | Active comparator | Continuous 28-day cycles of BSC only, azacitidine subcutaneously (SC) plus BSC, low-dose cytarabine (LDAC) SC plus BSC, or intermediate-dose cytarabine (IDAC) intravenously (IV) plus BSC. Subjects will be assigned by the investigator to one of the CCR treatment options based on the investigator's assessment of subjects' eligibility. Receives: Other: BSC; Drug: Azacitidine; Drug: Low-dose cytarabine (LDAC); Drug: Intermediate-dose cytarabine (IDAC) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall Survival (OS)
The time between randomization and death from any cause. Participants who drop-out or are alive at the end of trial will have their OS times censored at the time of last contact, as appropriate.
Measured: From randomization to death due to any cause (up to approximately 49 months)
Secondary outcomes (19)
Overall Response Rate
Number of participants with MLFS + CR + CRi + CRp + PR according to modified International Working Group Acute Myeloid Leukemia (IWG AML) response criteria. Complete response (CR) and morphologic leukemia-free state (MLFS) are defined as <5% blasts in a BM aspirate sample with marrow spicules and a count of ≥200 nucleated cells. There should be no blasts with Auer rods and no extramedullary disease. CR must also include: absolute neutrophil count (ANC) ≥1,000/μL, Platelet count ≥100,000/μL, and independent of red cell transfusions for ≥1 week before each response assessment. Complete remission with incomplete neutrophil recovery (CRi) is all criteria of CR except ANC. Complete remission with incomplete platelet recovery (CRp) is all criteria of CR except platelet count. Partial remission (PR) is defined as all hematologic criteria of CR with a >50% decrease in the percentage of BM blasts to 5% to 25%. (<5% considered if Auer rods are present).
Measured: From randomization up to study completion (approximately 78 months)
Event-Free Survival
Time from randomization to documented morphologic relapse after complete remission/complete remission with incomplete neutrophil recovery/complete remission with incomplete platelet recovery (CR/CRi/CRp), progressive disease (PD) or death from any cause, whichever occurs first. Morphologic Relapse after CR/CRi/CRp is defined as either reappearance of ≥ 5% blasts in the BM not attributable to any other cause or the development of extramedullary disease. PD is defined as a > 50% increase of BM blast count percentage from baseline to ≥ 20% for participants with 5 to 70% BM blasts at baseline or a doubling of absolute blast count in peripheral blood from baseline to ≥ 10 x 109/L (10,000/μL) for participants with > 70% BM blasts at baseline or the development of new extramedullary disease.
Measured: From randomization up to study completion (approximately 78 months)
Duration of Response
Time from first documented MLFS/CR/CRi/CRp/PR to documented morphologic relapse after CR/CRi/CRp/ PD or death due to any cause, whichever occurs first. CR and MLFS are defined as <5% blasts in a BM aspirate sample with marrow spicules + a count of ≥200 nucleated cells with no blasts with Auer rods + no extramedullary disease. CR must also include: ANC ≥ 1,000/μL, Platelet count ≥100,000/μL, + independent of red cell transfusions for ≥1 week before assessment. CRi is all criteria of CR except ANC. CRp is all criteria of CR except platelet count. PR is defined as all hematologic criteria of CR with >50% decrease in BM blasts to 5%-25%. Relapse after CR/CRi/CRp is defined as reappearance of ≥ 5% blasts in the BM not attributable to other cause or development of extramedullary disease. PD is defined as > 50% increase of BM blast count from baseline to ≥ 20% or a doubling of absolute blast count in peripheral blood from baseline to ≥ 10,000/μL or development of new extramedullary disease.
Measured: From randomization up to study completion (approximately 78 months)
Time to Response
Time from randomization to first documented MLFS/CR/CRi/CRp/PR. Complete remission (CR) and morphologic leukemia-free state (MLFS) are defined as <5% blasts in a BM aspirate sample with marrow spicules and a count of ≥200 nucleated cells. There should be no blasts with Auer rods and no extramedullary disease. CR must also include the following conditions: absolute neutrophil count (ANC) ≥1,000/μL, Platelet count ≥100,000/μL, and independent of red cell transfusions for ≥1 week before each response assessment. Complete remission with incomplete neutrophil recovery (CRi) is all criteria of CR except ANC. Complete remission with incomplete platelet recovery (CRp) is all criteria of CR except platelet count. partial remission (PR) is defined as all hematologic criteria of CR with a >50% decrease in the percentage of BM blasts to 5% to 25%. (<5% considered if Auer rods are present).
Measured: From randomization to to first documented MLFS/CR/CRi/CRp/PR (up to approximately 49 months)
Treatment Mortality at 30 Days
The number of participant deaths from any cause within 30 days of initiation of study treatment.
Measured: From first dose to 30 days after first dose
Treatment Mortality at 60 Days
The number of participant deaths from any cause within 60 days of initiation of study treatment.
Measured: From first dose to 60 days after first dose
One-Year Survival Rate
The proportion of participants alive at 1 year after randomization
Measured: From randomization up to 1 year post (approximately 12 months)
Overall Remission Rate
The number of participants with CR + CRi + CRp according to modified International Working Group Acute Myeloid Leukemia (IWG AML) response criteria. Complete remission (CR) is defined as <5% blasts in a BM aspirate sample with marrow spicules and a count of ≥200 nucleated cells. There should be no blasts with Auer rods and no extramedullary disease. CR must also include the following conditions: absolute neutrophil count (ANC) ≥1,000/μL, Platelet count ≥100,000/μL, and independent of red cell transfusions for ≥1 week before each response assessment. Complete remission with incomplete neutrophil recovery (CRi) is all criteria of CR except ANC. Complete remission with incomplete platelet recovery (CRp) is all criteria of CR except platelet count.
Measured: From randomization up to approximately 49 months
Complete Remission Rate
The number of participants with morphologic complete remission (CR) according to modified International Working Group Acute Myeloid Leukemia Response Criteria (IWG AML). CR is defined as less than 5% blasts in a BM aspirate sample with marrow spicules and with a count of at least 200 nucleated cells. There should be no blasts with Auer rods and absence of extramedullary disease; plus the following conditions: absolute neutrophil count (ANC) ≥1,000/μL, Platelet count ≥100,000/μL, and independent of red cell transfusions for ≥1 week before each response assessment.
Measured: From randomization up to approximately 49 months
Hematologic Improvement Rate
The number of participants with hematologic improvement neutrophil response (HI-N) + hematologic improvement platelet response (HI-P) + hematologic improvement erythroid response (HI-E) according to the International Working Group for Myelodysplastic Syndromes for Hematologic Improvement (IWG MDS HI) criteria. HI-E is defined as a hemoglobin increase by ≥ 1.5 g/dL and a relevant reduction in units of RBC transfusions by an absolute number of at least 4 RBC transfusions/8 week compared with the pretreatment transfusion number in the previous 8 week. HI-P is defined as an absolute increase of ≥ 30 X 10^9/L for participants starting with > 20 X and an increase from < 20 X 10^9/L to > 20 X 10^9/L and by at least 100%. HI-N is defined as At least 100% increase and an absolute increase > 0.5 X 10^9/L.
Measured: From randomization up to approximately 49 months
The Number of Participants That Underwent Hematopoietic Stem Cell Transplantation (HSCT)
The number of participants that underwent hematopoietic stem cell transplantation during the study.
Measured: From randomization up to approximately 49 months
Time to Treatment Failure
Time from randomization to discontinuation of study treatment due to any cause
Measured: From randomization to discontinuation of study treatment due to any cause (up to approximately 49 months)
The Number of Participants Experiencing Adverse Events (AEs)
The number of participants experiencing different types of adverse events (AE). An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. A Serious Adverse Event (SAE) is any AE occurring at any dose that: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or constitutes an important medical event. All AEs were coded using the MedDRA Version 22.0. Adverse events were analyzed in terms of treatment-emergent AEs (TEAEs). A treatment-related TEAE was defined as a TEAE that was suspected by the investigator to be related to study treatment. The severity was graded by the study personnel based on NCI National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03.
Measured: From randomization up to study completion (approximately 78 months)
The Percent of Participants Experiencing Clinically Significant Laboratory Abnormalities - Serum Chemistry
The percent of participants with clinically significant serum chemistry laboratory abnormalities. A clinically significant laboratory abnormality is defined as meeting Grade 3 or Grade 4 criteria according to the Common Terminology Criteria for Adverse Events (CTCAE). Grade 3 is defined as severe or medically significant but not immediately life threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care. Grade 4 is defined as life-threatening consequences; urgent intervention indicated. The chemistry panel includes sodium, potassium, calcium, magnesium, chloride, phosphorus, CO2, bicarbonate, blood urea nitrogen (BUN), creatinine, glucose, albumin, total protein, alkaline phosphatase (ALP), bilirubin (total and direct), uric acid, lactate dehydrogenase (LDH), AST/SGOT, ALT/SGPT, gamma glutamyl transpeptidase (GGT), amylase and lipase.
Measured: From first dose up to approximately 49 months
The Percent of Participants Experiencing Clinically Significant Laboratory Abnormalities - Hematology
The percent of participants with clinically significant hematology laboratory abnormalities. A clinically significant laboratory abnormality is defined as meeting Grade 3 or Grade 4 criteria according to the Common Terminology Criteria for Adverse Events (CTCAE). Grade 3 is defined as severe or medically significant but not immediately life threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care. Grade 4 is defined as life-threatening consequences; urgent intervention indicated. The hematology panel includes complete blood count (CBC) with differential, including red blood cell (RBC) count, hemoglobin, hematocrit, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), white blood cell (WBC) count (with differential), absolute neutrophil count (ANC) and platelet count.
Measured: From first dose up to approximately 49 months
The Percent of Participants Experiencing Clinically Significant Vital Sign Abnormalities
The percent of participants with clinically significant vital sign abnormalities including weight, temperature, blood pressure, pulse rate, and respiratory rate.
Measured: From first dose up to approximately 49 months
The Percentage of Participants Experiencing Clinically Significant Electrocardiogram (ECG) Abnormalities
The percent of participants with clinically significant ECG abnormalities. 12-lead ECG was assessed by a physician trained in ECG interpretation. Intervals including PR, QRS, QT and RR were collected, as well as heart rate and rhythm.
Measured: From first dose up to approximately 49 months
Change From Baseline in the European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire (EORTC QLQ-C30)
The change from baseline in the EORTC QLQ-C30 questionnaire. The EORTC QLQ-C30 is composed of 30 items that address general physical symptoms, physical functioning, fatigue and malaise, and social and emotional functioning. Subscale scores are transformed to a 0 to 100 scale, with higher scores on functional scales indicating better function and higher scores on symptom scales indicating worse symptoms. A change of at least 10 points on the standardized domain scores was required for it to be considered meaningful. Results obtained just prior to the start of study treatment on Day 1 of Cycle 1 will serve as the baseline values. If not available, the most recent screening results prior to the start of study treatment on Day 1 of Cycle 1 will be considered the baseline values.
Measured: From baseline to cycle 2 day 1 (up to approximately 1 month)
Change From Baseline in EQ-5D-5L Health Utility Index
The European Quality of Life 5D-5L Scale (EQ-5D-5L) assesses general health-related quality of life. Health is defined in 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Responses are coded so that a '1' indicates no problem, and '5' indicates the most serious problem. The responses for the 5 dimensions are combined in a 5-digit number. These health states are converted to a single index value using the crosswalk method to the EQ-5D-3L value set from the United Kingdom (UK). The EQ-5D-3L health utility index based on the UK population weights range from -0.594 to 1.0 with higher scores indicating higher health utility. Baseline results are obtained just prior to the start of study treatment on Day 1 of Cycle 1 and will serve as the baseline values.
Measured: From baseline up to cycle 2 day 1 (up to approximately 1 month)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Oct 2015 (estimated)
- Study start30 Dec 2015
- Primary completion17 Mar 2020
- Study completion25 Mar 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Leukemia, MyeloidStudies of the same condition, open and under way.
- More trials run by CelgeneThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 319 participants (actual)
Sponsor and investigators
- Lead sponsor
- Celgene
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Bristol-Myers Squibb, Study director, Bristol-Myers Squibb
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02577406
- Sponsor's protocol ID
- AG-221-AML-004
- Acronym
- IDHENTIFY
- Status last verified
- May 2025
- First submitted
- 14 Oct 2015
- Last updated
- 18 May 2025
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- Expanded access
- Available
Publications
Montesinos P, Fathi AT, de Botton S, Stein EM, Zeidan AM, Zhu Y, Prebet T, Vigil CE, Bluemmert I, Yu X, DiNardo CD. Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib: pooled analysis from clinical trials. Blood Adv. 2024 May 28;8(10):2509-2519. doi: 10.1182/bloodadvances.2023011914.
PubMed 38507688
Study at a glance
From the registry record, last updated by the sponsor on 18 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 3, Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation
- ClinicalTrials.gov ID
- NCT02577406
- Acronym / sponsor ID
- IDHENTIFY / AG-221-AML-004
- Conditions
- Leukemia, Myeloid, Isocitrate Dehydrogenase
- Keywords
- AG-221, CC-90007, Efficacy, Safety, Leukemia, Acute myeloid meukemia, Isocitrate dehydrogenase 2 mutation, Enasidenib
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 319 participants (actual)
- Lead sponsor
- CelgeneIndustry (pharma, biotech, devices)
- Study start
- 30 Dec 2015 (actual)
- Primary completion
- 17 Mar 2020 (actual)
- Study completion
- 25 Mar 2024 (actual)
- First posted
- 16 Oct 2015 (estimated)
- Results
- Posted 10 Sep 2022
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is an international, multicenter, open-label, randomized, Phase 3 study comparing the efficacy and safety of AG-221 versus conventional care regimens (CCRs) in subjects 60 years or older with acute myeloid leukemia (AML) refractory to or relapsed after second- or third-line AML therapy and positive for an isocitrate dehydrogenase (IDH2) mutation.
Detailed description
Acute myeloid leukaemia (AML) is a form of cancer that is common in older patients. Mutations in the isocitrate dehydrogenase enzyme 2 (IDH2) have been found in approximately 15% of patients with AML.
The outcome of first line chemotherapy treatment is poor and many patients fail to attain complete remission (CR, ie refractory) or will eventually relapse. There is no single standard of care for relapsed or refractory AML. Since the prognosis is very poor there is a great need for new therapies.
Inhibition of the mutant IDH2 enzyme may represent a promising targeted therapy for AML. AG-221 is a small molecule inhibitor of the IDH2 enzyme, designed to preferentially target the mutant IDH2 variants. Data from the ongoing first-in-human study has shown AG-221 to be generally well tolerated and demonstrated CR in patients with IDH2 mutation positive relapsed or refractory AML.
The study purpose is to test the safety and efficacy of AG-221 compared with conventional care regimens (CCR), which include best supportive care (BSC) only, azacitidine plus BSC, low-dose cytarabine plus BSC or intermediate-dose cytarabine plus BSC, in patients with late stage AML refractory to or relapsed after second or third line therapy and positive for the IDH2 mutation. Patients will be randomly assigned to receive open-label tablets of AG-221 or one of the CCR on continuous 28-day treatment cycles. The trial duration is expected to be 78 months which includes 42 months enrollment, approximately 7 months treatment and a follow-up period.
Study procedures include: vital signs, physical exams, ECGs, ECHO, urine/blood samples, bone marrow aspirates and/or biopsies and peripheral blood to test for IDH2 and assess treatment response. Bone marrow, blood, cheek swab samples will be used for genetic tests.
This study is being sponsored by Celgene Corporation. Approximately 316 participants will take part in the study.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| AG-221 plus Best supportive care (BSC) | Experimental | Drug: AG-221, Other: BSCContinuous 28-day cycles of AG 221 100 mg orally (PO) once a day (QD) for 28 days, plus BSC. |
| Conventional care regimen (CCR) | Active comparator | Other: BSC, Drug: Azacitidine, Drug: Low-dose cytarabine (LDAC), Drug: Intermediate-dose cytarabine (IDAC)Continuous 28-day cycles of BSC only, azacitidine subcutaneously (SC) plus BSC, low-dose cytarabine (LDAC) SC plus BSC, or intermediate-dose cytarabine (IDAC) intravenously (IV) plus BSC. Subjects will be assigned by the investigator to one of the CCR treatment options based on the investigator's assessment of subjects' eligibility. |
Who may qualify
- Ages
- 60 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (24 listed)
- Subject is ≥ 60 years of age at the time of signing the ICF
- Subject has primary (ie, de novo) or secondary (progression of MDS or myeloproliferative neoplasms ([MPN], or therapy-related) AML according to WHO classification (Appendix B)
- Subject has received second- or third-line of AML therapy (see Appendix G for the definition of prior AML line; note that, for subjects having AML secondary to prior higher risk [Intermediate-2 or High risk according to the International Prognostic Scoring System] MDS treated with a hypomethylating agent [eg, azacitidine or decitabine], the hypomethylating therapy can be counted as a line if there is disease progression to AML during or shortly [eg, within 60 days] after the hypomethylating therapy.)
- Subject has the following disease status:
- at least 5% leukemic blasts in bone marrow (the minimum number of treatment cycles of the intensive therapy is per the investigator's discretion); or
Key exclusion criteria (30 listed)
- Subject is suspected or proven to have acute promyelocytic leukemia based on morphology, immunophenotype, molecular assay, or karyotype
- Subject has AML secondary to chronic myelogenous leukemia
- Subject has received a targeted agent against an IDH2 mutation
- Subject has received systemic anticancer therapy or radiotherapy < 14 days prior to the start of study treatment. Note that hydroxyurea is allowed prior to the start of study treatment for the control of leukocytosis (however, hydroxyurea should not be given within 72 hours prior to and after administration of azacitidine).
- Subject has received non-cytotoxic or investigational agents < 14 days or 5 half-lives, whichever is longer, prior to the start of study treatment
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AG-221Continuous 28-day cycles of AG 221 100 mg orally (PO) once a day (QD) for 28 days | Drug | AG-221 plus Best supportive care (BSC) |
| BSCBest supportive care includes, hydroxyurea for leukocytosis and/or differentiation-like syndrome, anti-infectives, analgesics, antiemetics, antipyretics, transfusions and nutritional support | Other | AG-221 plus Best supportive care (BSC), Conventional care regimen (CCR) |
| Azacitidinecontinuous 28-day cycles of azacitidine 75 mg/m2/day SC for 7 days, plus BSC | Drug | Conventional care regimen (CCR) |
| Low-dose cytarabine (LDAC)continuous 28-day cycles of cytarabine 20 mg SC twice a day (BID) for 10 days, plus BSC | Drug | Conventional care regimen (CCR) |
| Intermediate-dose cytarabine (IDAC)28-day cycles of cytarabine 0.5 to 1.5 g/m2/day IV for 3 to 6 days, per standard institutional practice, plus BSC; only BSC given after IDAC therapy concludes per standard institutional practice | Drug | Conventional care regimen (CCR) |
Primary outcome
Overall Survival (OS)
Time frame: From randomization to death due to any cause (up to approximately 49 months)
The time between randomization and death from any cause. Participants who drop-out or are alive at the end of trial will have their OS times censored at the time of last contact, as appropriate.
19 secondary outcomes
Overall Response Rate
Time frame: From randomization up to study completion (approximately 78 months)
Event-Free Survival
Time frame: From randomization up to study completion (approximately 78 months)
Duration of Response
Time frame: From randomization up to study completion (approximately 78 months)
Time to Response
Time frame: From randomization to to first documented MLFS/CR/CRi/CRp/PR (up to approximately 49 months)
Treatment Mortality at 30 Days
Time frame: From first dose to 30 days after first dose
Treatment Mortality at 60 Days
Time frame: From first dose to 60 days after first dose
One-Year Survival Rate
Time frame: From randomization up to 1 year post (approximately 12 months)
Overall Remission Rate
Time frame: From randomization up to approximately 49 months
Complete Remission Rate
Time frame: From randomization up to approximately 49 months
Hematologic Improvement Rate
Time frame: From randomization up to approximately 49 months
The Number of Participants That Underwent Hematopoietic Stem Cell Transplantation (HSCT)
Time frame: From randomization up to approximately 49 months
Time to Treatment Failure
Time frame: From randomization to discontinuation of study treatment due to any cause (up to approximately 49 months)
The Number of Participants Experiencing Adverse Events (AEs)
Time frame: From randomization up to study completion (approximately 78 months)
The Percent of Participants Experiencing Clinically Significant Laboratory Abnormalities - Serum Chemistry
Time frame: From first dose up to approximately 49 months
The Percent of Participants Experiencing Clinically Significant Laboratory Abnormalities - Hematology
Time frame: From first dose up to approximately 49 months
The Percent of Participants Experiencing Clinically Significant Vital Sign Abnormalities
Time frame: From first dose up to approximately 49 months
The Percentage of Participants Experiencing Clinically Significant Electrocardiogram (ECG) Abnormalities
Time frame: From first dose up to approximately 49 months
Change From Baseline in the European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire (EORTC QLQ-C30)
Time frame: From baseline to cycle 2 day 1 (up to approximately 1 month)
Change From Baseline in EQ-5D-5L Health Utility Index
Time frame: From baseline up to cycle 2 day 1 (up to approximately 1 month)
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 May 2025.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 38507688Montesinos P, Fathi AT, de Botton S, Stein EM, Zeidan AM, Zhu Y, Prebet T, Vigil CE, Bluemmert I, Yu X, DiNardo CD. Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib: pooled analysis from clinical trials. Blood Adv. 2024 May 28;8(10):2509-2519. doi: 10.1182/bloodadvances.2023011914.
- BMS Clinical Trial InformationLink provided by the sponsor.
- BMS Clinical Trial Patient RecruitingLink provided by the sponsor.
Related trials for Leukemia, Myeloid
RecruitingPhase 1
A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML
AML (Acute Myeloid Leukemia)
RecruitingPhase 1
Vididencel in CML-CP Patients With MRD
CML (Chronic Myelogenous Leukemia)
RecruitingPhase 2
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm
Active, not recruitingPhase 2
Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia
Adult Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
RecruitingPhase 1/2
Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
Acute Biphenotypic Leukemia, Acute Myeloid Leukemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Bristol-Myers Squibb study director
Bristol-Myers Squibb
93 sites in 18 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing AG-221, BSC and Azacitidine in people with Leukemia, Myeloid and Isocitrate Dehydrogenase, run by Celgene at 93 sites in 18 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 24 inclusion and 30 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 May 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 93 sites in United States, China, France, Germany, Italy and 13 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 10 Sep 2022). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall Survival (OS) (time frame: From randomization to death due to any cause (up to approximately 49 months)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02577406, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 May 2025.